Stem Cells After Peripheral Mobilization and Harvest

Orthopedic Disorder Clinical Trial

Official title:

Quantification and Qualification of Stem Cells After Peripheral Mobilization and Harvest for Orthopaedic Point of Care Application

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03381599
• Other study ID #: 16398
• Status: Completed
• Phase: Phase 1
• Start date: March 28, 2018
• Est. completion date: September 4, 2019

Study information

• Verified date: March 2020
• Source: Andrews Research & Education Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed study is a controlled laboratory study where stem cell content of bone marrow aspirate will be compared prior to and following pharmaceutical mobilization. Participants who meet the inclusion/exclusion criteria will have a bone marrow sample taken from the iliac crest. The sample will be tested to determine stem cell content and for the presence of proteins which are of interest in orthopedic treatments. Thirty days following the baseline bone marrow collection, participants will receive a subcutaneous injection of Filgrastim daily for four serial days. On the fifth day, a peripheral blood sample will be taken and processed.

Description:

Orthopaedic practitioners have begun to augment surgical procedures and treat degenerative conditions, such as osteoarthritis, with injections of bone marrow aspirate. Clinical application studies have suggested that success is dependent upon the number of stem cells harvested and utilized. Pharmaceutical mobilization, with agents such as Filgrastim (Neupogen), followed by peripheral harvest of stem cells has supplanted bone marrow aspirate for hematologic oncologic clinical practice of stem cell transplant, with established safety and efficacy.

The proposed study is a controlled laboratory study where stem cell content of bone marrow aspirate will be compared prior to and following pharmaceutical mobilization using Filmgrastim (Neupogen). Participants will undergo a screening examination consisting of a physical examination and blood work. A standard venipuncture will be performed in the left or right arm and a 5.0 mL vacationer tube will be filled with blood and a 60 mL syringe pre-filled with anticoagulant will be filled with blood. The blood will be analyzed with flow cytometry, a histologic smear, a complete blood count (CBC) with white blood cell (WBC) differential, and chemokine/cytokine analyst with ELISA testing. The blood in the 60.0 mL syringe will be processed with the Arthrex Angel system. The buffy coat component of the blood will be analyzed.

On a separate day, participants who meet the inclusion/exclusion criteria will have a bone marrow sample taken from the iliac crest. The participant will lay on their side and 20 mL of 1% lidocaine will be injected into the anticipated incision site. A 1 cm incision in the skin, advancing a trotter into the bone marrow cavity, aspirating 5 cc of bone marrow with a 5 mL syringe and placement of the sample into a 5 mL vaccutainer syringe, and filling a 60.0 ml syringe pre-filled with 8 ml of citrate anticoagulant with bone marrow aspirate. The bone marrow in the 5 mL vaccutainer will be analyzed by flow cytometry, a histologic smear, a CBC with WBC differential, and chemokine/cytokine analysis with ELISA testing. The bone marrow in the 60.0 mL syringe will be processed with the Arthrex Angel system. The sample will be tested to determine stem cell content and for the presence of proteins which are of interest in orthopedic treatments.

Thirty days following the baseline bone marrow collection, participants will receive a subcutaneous injection of Filgrastim daily for four serial days. A blood sample of 5 mL will be collected each day of the injection to obtain a CBC and WBC differential. On the fifth day, a peripheral blood sample will be taken and processed following the same procedures as the first sample.

It is hypothesized that with a pharmaceutical mobilization method and the Arthrex Angel system, clinicians can harvest more stem cells than with bone marrow aspiration alone.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: September 4, 2019
• Est. primary completion date: September 4, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 19 Years to 39 Years

Eligibility

Inclusion Criteria:

• Weight 110-220 pounds

• Healthy

Exclusion Criteria:

• Previous allergic reaction to Filgrastim, lidocaine, or other injectable numbing agent

• White blood count greater than 20,000/mcL

• Latex allergy

• Diabetes

• Any autoimmune disorder

• Any blood disorder requiring immunosuppression

• Cancer

• Ongoing infectious disease

• Significant cardiovascular, renal, hepatic, or pulmonary disease

• Sickle cell or other blood disorders

• Presence of abdominal tenderness with palpation upon physical examination

• Signs of splenomegaly upon physical examination

• Abnormal lung fields upon physical examination

Related Conditions & MeSH terms

• Musculoskeletal Diseases
• Orthopedic Disorder
• Stem Cells

Intervention

Drug:
• Filgrastim Injection
Filgrastim of 10 ug/kg/day will be given for four serial days.

Locations

Country	Name	City	State
United States	Auburn University	Auburn	Alabama

Sponsors (3)

Lead Sponsor	Collaborator
Andrews Research & Education Foundation	Arthrex, Inc., Auburn University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Stem Cell Count	Quantity and quality of the harvested stem cells	Baseline to Day 32
Secondary	Complete blood count	Participants white blood cell count/differential	Day 1, Day 2, Day 28, Day 29, Day 30, Day 31 Day 32
Secondary	Chemokine/Cytokine	Participants chemokine/cytokine count	Day 1, Day 2, Day 28, Day 29, Day 30, Day 31 Day 32